Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Please refer to the KEYTRUDA Summary of Product Characteristics and Risk Minimisation Materials before prescribing KEYTRUDA. Risk Minimisation Materials are available online, from your MSD representative or from MSD Medical Information (Email: medicalinformationuk@msd.com, Phone: 0208 154 8000).
Cervical cancer indications
Classical Hodgkin lymphoma indications
Colorectal cancer indications
Endometrial carcinoma indications
Head and neck squamous cell carcinoma indications
Melanoma indications
MSI-H or dMMR cancer indications
Non-small cell lung cancer indications
Oesophageal carcinoma indications
Renal cell carcinoma indications
Triple-negative breast cancer indications
Urothelial carcinoma indications
KEYTRUDA is a selective monoclonal antibody that blocks the programmed cell death-1 (PD-1) protein pathway, potentiating T-cell responses, including anti-tumour responses.1,2,3
When functioning properly, T cells are activated and can attack tumour cells1,2,3
Some tumours can evade the immune system through the PD-1 pathway. On the surface of tumour cells the dual PD-1 ligands, PD-L1 and PD-L2, bind to the PD-1 receptors on T cells to inactivate them, allowing tumour cells to evade detection1,2,3
By inhibiting this process, KEYTRUDA reactivates tumour-specific cytotoxic T lymphocytes and anti-tumour immunity1,2,3
PD-1 = Programmed Cell Death-1; PD-L1 = Programmed Cell Death Ligand-1; PD-L2 = Programmed Cell Death Ligand-2.
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
GB-PDO-02107 | Date of Preparation: June 2022